Point72 Asset Management L.P. increased its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 151.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 437,700 shares of the company's stock after purchasing an additional 263,500 shares during the period. Point72 Asset Management L.P. owned approximately 1.48% of Dianthus Therapeutics worth $11,984,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in DNTH. Janus Henderson Group PLC grew its position in Dianthus Therapeutics by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 949,334 shares of the company's stock worth $25,936,000 after purchasing an additional 273,670 shares during the last quarter. HighVista Strategies LLC bought a new position in shares of Dianthus Therapeutics during the 3rd quarter worth about $542,000. Fred Alger Management LLC boosted its position in shares of Dianthus Therapeutics by 52.5% during the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock valued at $264,000 after acquiring an additional 3,316 shares in the last quarter. Braidwell LP boosted its stake in shares of Dianthus Therapeutics by 34.6% in the 3rd quarter. Braidwell LP now owns 493,687 shares of the company's stock valued at $13,517,000 after purchasing an additional 126,836 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $821,000. Institutional investors own 47.53% of the company's stock.
Dianthus Therapeutics Stock Up 3.1 %
DNTH stock traded up $0.73 during mid-day trading on Friday, reaching $24.39. 167,938 shares of the company traded hands, compared to its average volume of 341,741. Dianthus Therapeutics, Inc. has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The firm's 50 day moving average price is $26.44 and its 200 day moving average price is $26.53. The stock has a market cap of $721.94 million, a price-to-earnings ratio of -9.76 and a beta of 1.74.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. Raymond James upped their target price on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an "outperform" rating in a research report on Friday, November 8th. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, Oppenheimer increased their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $46.43.
Check Out Our Latest Stock Analysis on Dianthus Therapeutics
About Dianthus Therapeutics
(
Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Further Reading
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.